EPHB6

Ephrin type-B receptor 6 · O15197 · EPHB6 on Sugi Atlas →

52,089 patent compounds predicted against EPHB6, 44,106 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
SCHEMBL41486	0.44	2/20
Gefitinib (SCHEMBL7866)	1.00	1/20
Nilotinib (SCHEMBL7901)	1.00	1/20
Erlotinib (SCHEMBL8413)	1.00	1/20
Vandetanib (SCHEMBL9044)	1.00	1/20
Saracatinib (SCHEMBL41547)	1.00	1/20
Canertinib (SCHEMBL54837)	1.00	1/20
Cediranib (SCHEMBL63147)	1.00	1/20
Quizartinib (SCHEMBL72923)	1.00	1/20
Pha-665752 (SCHEMBL93654)	1.00	1/20
Pha-665752 (SCHEMBL93655)	1.00	1/20
Pha-665752 (SCHEMBL93656)	1.00	1/20
Pha-665752 (SCHEMBL93657)	1.00	1/20
Ruxolitinib (SCHEMBL99225)	1.00	1/20
Ruxolitinib (SCHEMBL101279)	1.00	1/20
Plx-4720 (SCHEMBL133733)	1.00	1/20
Quizartinib (SCHEMBL74121)	0.99	1/20
Gefitinib (SCHEMBL11776)	0.98	1/20
SCHEMBL99245	0.98	1/20

Clinical trials — most relevant to EPHB6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function	nan	COMPLETED
Blood Vessel Study	nan	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Genetics of Arteriovenous Malformations	nan	UNKNOWN
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers	nan	RECRUITING
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection	nan	NOT_YET_RECRUITING
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Family Blood Pressure Program - SAPPHIRe Network	nan	COMPLETED
Family Blood Pressure Program - GENOA	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHB6 binder may also engage these)

Protein	Name	Similarity
P0C0K6	—	1.000	P0C0K6 →
Q8BYG9	—	1.000	Q8BYG9 →
O08644	—	1.000	O08644 →
P0C0K7	—	0.998	P0C0K7 →
EPHB4	Ephrin type-B receptor 4	0.998	landscape →
O09127	—	0.996	O09127 →
Q63474	—	0.993	Q63474 →
EPHA8	Ephrin type-A receptor 8	0.993	landscape →
INSRR	Insulin receptor-related protein	0.993	landscape →
Q03146	—	0.993	Q03146 →
P51840	—	0.993	P51840 →
Q92729	—	0.992	Q92729 →
TNK1	Non-receptor tyrosine-protein kinase TNK1	0.991	landscape →
TIE1	Tyrosine-protein kinase receptor Tie-1	0.991	landscape →
EPHA1	Ephrin type-A receptor 1	0.991	landscape →
P52785	—	0.991	P52785 →
P55203	—	0.991	P55203 →
P51839	—	0.990	P51839 →
JAK3	Tyrosine-protein kinase JAK3	0.990	landscape →
O19179	—	0.990	O19179 →
Q5JZY3	—	0.990	Q5JZY3 →
P54761	—	0.990	P54761 →
DDR1	Epithelial discoidin domain-containing receptor 1	0.990	landscape →
Q62190	—	0.989	Q62190 →
Q9WTL4	—	0.989	Q9WTL4 →
Q9R1A3	—	0.989	Q9R1A3 →
P14617	—	0.988	P14617 →
CSF1R	Macrophage colony-stimulating factor 1 receptor	0.988	landscape →
O75064	—	0.988	O75064 →
Q7YR43	—	0.988	Q7YR43 →